Capacity adiposity indices to identify metabolic syndrome in subjects with intermediate cardiovascular risk (MARK study)
dc.contributor.author
dc.date.accessioned
2020-06-15T09:09:21Z
dc.date.available
2020-06-15T09:09:21Z
dc.date.issued
2019-01-25
dc.identifier.uri
dc.description.abstract
Background
Obesity increases mortality, and is linked to cardiovascular diseases and metabolic syndrome (MetS). Therefore, the purpose of this study was to analyze the ability of different adiposity indices to identify subjects with MetS among people with intermediate cariovascular
risk.
Materials and methods
The cross-sectional study involved 2478 subjects, recruited by the MARK study. Adiposity
measures: general adiposity by body mass index (BMI), central adiposity by waist-to-height
ratio (WHtR), fat mass percent by the Clı´nica Universidad de Navarra—body adiposity estimator (CUN-BAE), percentage of body fat and of visceral adipose tissue by body roundness
index (BRI) and visceral obesity and general adiposity with body shape index (ABSI). The
diagnosis of MetS was made in accordance with the criteria established in the international
consensus of the Joint Scientific Statement National Cholesterol Education Program III.
Results
The highest correlation coefficients were obtained by the glycemic components (HbA1c and
FPG) of the MetS and ranged from 0.155 to 0.320. The exception was ABSI, which showed
lower values in the global analysis and in the males. Values of the area under the ROC
curve with the adiposity indices ranged from 0.773 with the BMI in males to 0.567 with ABSI in males. In the logistic regression analysis, all adiposity factors, except ABSI, showed similar OR values of MetS after adjusting for possible confounding factors. In the global analysis,
the adiposity index that showed a highest OR of MetS was CUN-BAE (OR 5.50; 95% CI
4.27–7.09). In the analysis by gender, the highest ORs were BMI in males (OR 5.98; 95% CI
4.70–7.60) and both WHtR and BRI in females (OR 4.15; 95% CI 3.09–5.58).
Conclusion
All adiposity indices, except for ABSI, show an association with MetS and similar ability to
detect subjects with MetS among people with intermediate cariovascular risk
dc.description.sponsorship
This work was supported by grants from
the Spanish Ministry of Science and Innovation
(MICINN), the Carlos III Health Institute/European
Regional Development Fund (ERDF) (MICINN,
ISCIII/FEDER) (Red RedIAPP RD06/0018,
Research Groups: RD16/0007/0003, RD16/0007/
0004, RD16/0007/0008), the Health Research Fund (PI10/01088, PI10/02077, PI10/02043; PI13/
01930), and the Regional Health Management of
Castile and Leo´n (GRS 635/A/11; GRS 906/B/14
dc.format.mimetype
application/pdf
dc.language.iso
eng
dc.publisher
Public Library of Science
dc.relation.isformatof
Reproducció digital del document publicat a: https://doi.org/10.1371/journal.pone.0209992
dc.relation.ispartof
PLoS ONE, 2019, vol. 14, núm. 1, p. e0209992
dc.relation.ispartofseries
Articles publicats (D-CM)
dc.rights
Attribution 4.0 International
dc.rights.uri
dc.title
Capacity adiposity indices to identify metabolic syndrome in subjects with intermediate cardiovascular risk (MARK study)
dc.type
info:eu-repo/semantics/article
dc.rights.accessRights
info:eu-repo/semantics/openAccess
dc.type.version
info:eu-repo/semantics/publishedVersion
dc.identifier.doi
dc.type.peerreviewed
peer-reviewed
dc.identifier.eissn
1932-6203